Pfizer Stock Rebound Bet: Why the Beaten-Down Healthcare Giant Is Back in Focus
Pfizer stock picked up 1.5% to hit $26.07 as of 10:58 a.m. EDT on Monday, bringing the company’s market value to roughly $149 billion. Investors seem willing to revisit the name after a steep drop from its COVID-era highs, with attention zeroing in on three main issues: looming patent expirations, a late-stage push into the GLP-1 weight-loss drug market, and whether Pfizer has enough cash to keep its dividend intact.
